Skip to main content
OpenTrials
Completed

NCT Number: NCT05414955

Boom-IBD Clinical Trial

Feasibility study of neuromodulation in patients with IBD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

IBD

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Phillip Fleshner, Inc., Los Angeles, California, United States

Loading trial locations.

About this study

The study will evaluate responses of patients with IBD treated with neuromodulation at various intervals.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

General Inclusion Criteria:

  • Male or female
  • 18 to 75 years of age
  • Diagnosed with Crohn's Disease or ulcerative colitis
  • Ability and willingness to consent to participate by signing the informed consent form
  • Ability to comply with the protocol and willingness to comply with all follow-up requirements
  • Still have part or all of their colon

General Exclusion Criteria (The subject must not meet ANY of the following criteria):

  • Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound the results of the study
  • Any psychiatric or personality disorder at the discretion of the study investigator
  • Any active bacterial infection with a risk of bacteremia or sepsis (e.g. presence of abscess)
  • Active clostridium difficile infection of the colon
  • Active cytomegalovirus (CMV) infection of the colon
  • Evidence of colonic perforation
  • Fulminant colitis requiring emergency surgery
  • Microscopic, ischemic or infectious colitis
  • Unresected neoplasia of the colon
  • Colonic stricture unable to pass a colonoscope
  • History of cancer including melanoma (except for localized skin cancers) within 2 years
  • Participation in another clinical trial within the past 30 days of device implant
  • Investigational drug for the treatment of inflammatory bowel disease within 6 months of device implant
  • Inability to operate the patient programmer

Treatment and study plan

Neuromodulation

Device

Neuromodulation

Primary outcomes

  1. Disease Activity Index

    Time frame: up to 1 year

    CDAI (Crohn's Disease Activity Index Score) or MAYO Score (ulcerative colitis)

Sponsors and collaborators

Lead sponsor

Boomerang Medical

Industry

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jun 10, 2022
Registry last updated
Jun 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.